News

Video

Efficacy and Safety of Fruquintinib in Patients With Metastatic Colorectal Cancer According to Prior Treatment Sequence in the Refractory Setting: Results From FRESCO and FRESCO-2

Author(s):

Tanios Bekaii-Saab, MD

A phase 3, randomized, double-blind, placebo-controlled study to determine if prior TAS-102 and/or regorafenib treatment status and sequence affect the efficacy and safety of fruquintinib in patients with mCRC. This study used data from both FRESCO (NCT02314819) and FRESCO-2 (NCT04322539).

Related Videos
Arvind N. Dasari, MD, MS
Chih-Yi Liao, MD
John H. Strickler, MD
Anthony B. El-Khoueiry, MD
Michael Cecchini, MD, associate professor, medicine (medical oncology), co-director, Colorectal Program, Center for Gastrointestinal Cancers, medical oncology section lead, National Accreditation Program for Rectal Cancer, Internal Medicine, co-director, GI Clinical Research Team, Yale School of Medicine
Craig E. Devoe, MD, MS
Ciara Kelly, MBBCh, BAO
Ciara Kelly, MBBCh, BAO
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Aparna Parikh, MD
Related Content
FDA
September 5th 2024

FDA Awards Orphan Drug Designation to ABD-147 for Neuroendocrine Carcinoma

Oncology Unplugged
August 21st 2024

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

Arvind Dasari, MD, MS, associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center
September 1st 2024

Targeted Therapy, Vaccines, and Second-Generation Checkpoint Inhibitors Seek to Redefine mCRC Treatment

Heinz-Josef Lenz, MD, FACP, about the prognostic and predictive value of HER2 gene expression for patients with KRAS wild-type metastatic colorectal cancer (mCRC). Lenz is a professor in the Department of Medicine and the Department of Preventive Medicine in the Division of Oncology at the University of Southern California (USC) Keck School of Medicine in Los Angeles. He also serves as the associate director of Clinical Research, chair of the Gastrointestinal Oncology Program, and co-director of the Colorectal Center at the USC Norris Comprehensive Cancer Center
June 3rd 2024

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

Weiguo Su, PhD, of HUTCHMED
August 30th 2024

sNDA Withdrawn for Fruquitinib Plus Paclitaxel in Second-Line Gastric Cancer in China

Hugh S. Griffith, MBA
August 30th 2024

NuTide:323 Study of NUC-3373 Regimen in Second-Line CRC is Discontinued